SWE
Toggle navigation
English
Svenska
About Us
The Company
Board & Management
Scientific Advisory Board
Scientific Publications
Events & Mediawatch
Contact Us
Diabetes
Products
Clinical Trials
Investors
Investor Relations
CEO Comments
Corporate Governance
Press Releases
Financial Reports
Skip Navigation Links
Home
»
Investors
»
Press Releases
2021
2020
2019
2018
2017
2016
2015
2014
2013
Former Diamyd Medical
Press Releases
1/20/2021
Quarterly Report I 20/21
1/14/2021
Positive safety evaluation of Remygen
®
in high dose and in combination with Alprazolam gives the go-ahead for the continuation of the trial
1/12/2021
Meta-analysis updated with DIAGNODE-2 results provides further support for a precision medicine approach using Diamyd
®
Order GAD for preclinical research
ORDER
©
Privacy Policy
|
Cookie Policy
Share This Page
select
Facebook
Twitter
LinkedIn
Google Plus
Pinterest
Tumblr
StumbleUpon
Blogger
MySpace
Digg
Reddit
Email
GAD PRODUCTS
Order GAD for preclinical research